https://www.insidemf.com/
CTI BioPharma Corp. is a Seattle based biopharmaceutical company focused on the development and commercialization of novel therapies that address unique unmet medical needs for patients suffering from blood-related cancers. Pacritinib, our lead product candidate is in development for the treatment of myelofibrosis which has the potential to fulfill a significant treatment gap in the management of these patients due to it’s unique clinical profile.
At CTI, we are resolute in our commitment to deliver new medicines to patients with blood-related cancers who have limited treatment options. With deep hematology-oncology expertise, we're motivated to shift the treatment paradigm.
By identifying specific patient communities currently underserved by existing therapies and uncovering the scientific factors driving their diseases, we aim to advance the development of therapies that are potentially less toxic and more effective at treating patients.
Press Releases